REG - Smith & Nephew Plc - Director/PDMR Shareholding
11/03/2025 15:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250311:nRSK2445Aa&default-theme=true
RNS Number : 2445A Smith & Nephew Plc 11 March 2025
SMITH & NEPHEW PLC
11 March 2025
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
This announcement is made in accordance with the UK Market Abuse Regulation
(Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018).
1. VESTING OF SHARE AWARDS UNDER THE GLOBAL SHARE PLAN 2020
On 11 March 2025, the Company received notification of the following
transactions in US$0.20 ordinary shares (the "Shares") in Smith & Nephew
plc (the "Company") following the vesting of awards under the Smith &
Nephew Global Share Plan 2020.
i. VESTING OF 2022 PERFORMANCE SHARE PROGRAMME AWARDS MADE UNDER THE SMITH
& NEPHEW GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 20 May 2022, and
vested on 9 March 2025 at 59.3% of target for PDMRs who were members of the
Company's Executive Committee on the date of grant, and 78.1% for other PDMRs
appointed to the Executive Committee subsequent to the date of grant. A
number of Shares were sold to cover taxation obligations arising on the
vesting of the awards. The number of Shares acquired includes the dividend
equivalent Shares which participants receive on vested Shares. The table
below sets out the number of shares under award which vested. The remaining
shares under award have lapsed.
The following relates to individuals included in the below notification:
Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Vesting of Smith & Nephew Global Share Plan 2020: Performance Share
Programme awards granted on 20 May 2022, and subsequent sale of shares to
cover tax liability
Date of Transaction 9 March 2025 (vesting) and 10 March 2025 (market sale)
Place of Transaction London Stock Exchange (XLON)
Name Price (£) Volume Aggregated information
(Position) Status
Helen Barraclough PDMR 11.441599 18,951 (of which 8,939 were sold and 10,012 retained) N/A Single Transaction
(Group General Counsel and Company Secretary)
Paul Connolly PDMR 11.441599 23,831 (of which 8,143 were sold and 15,688 retained) N/A Single Transaction
(President Global Operations)
Phil Cowdy PDMR 11.441599 20,420 (of which 9,632 were sold and 10,788 retained) N/A Single Transaction
(Chief Corporate Development and Corporate Affairs Officer)
Craig Gaffin PDMR 11.441599 10,859 (of which 3,232 were sold and 7,627 retained) N/A Single Transaction
(President, Global Orthopaedics)
Mizanu Kebede PDMR 11.441599 24,368 (of which 9,009 were sold and 15,359 retained) N/A Single Transaction
(Chief Quality & Regulatory Affairs Officer)
Elga Lohler PDMR 11.441599 29,821 (of which 11,866 were sold and 17,955 retained) N/A Single Transaction
(Chief HR Officer)
Vasant Padmanabhan PDMR 11.441599 29,009 (of which 10,772 were sold and 18,237 retained) N/A Single Transaction
(President Research & Development ENT)
Alison Parkes PDMR 11.441599 7,010 (of which 2,854 were sold and 4,156 retained) N/A Single Transaction
(Chief Compliance Officer)
Scott Schaffner PDMR 11.441599 12,909 (of which 4,794 were sold and 8,115 retained) N/A Single Transaction
(President Sports Medicine)
All figures in these columns are stated to 6 decimal places where applicable.
ii. FINAL VESTING OF 2022 DEFERRED BONUS SHARE AWARDS MADE UNDER THE
GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 9 March 2022 with
vesting in equal tranches on the first, second and third anniversary of grant.
A number of Shares were sold to cover taxation obligations arising on the
vesting of the awards. The number of Shares acquired includes the dividend
equivalent Shares which participants receive on vested Shares.
The following relates to individuals included in the below notification:
Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Final vesting on 9 March 2025 of Deferred Bonus Share awards, granted on 9
March 2022 under the Smith & Nephew Global Share Plan 2020, and subsequent
sale of shares to cover tax liability
Date of Transaction 9 March 2025 (vesting) and 10 March 2025 (market sale)
Place of Transaction London Stock Exchange (XLON)
Name Price (£) Volume Aggregated information
(Position) Status
Helen Barraclough PDMR 11.441599 1,815 (of which 857 were sold and 958 retained) N/A Single Transaction
(Group General Counsel and Company Secretary)
Phil Cowdy PDMR 11.441599 2,976 (of which 1,404 were sold and 1,572 retained) N/A Single Transaction
(Chief Corporate Development and Corporate Affairs Officer)
Craig Gaffin PDMR 11.441599 896 (of which 267 were sold and 629 retained) N/A Single Transaction
(President, Global Orthopaedics)
Mizanu Kebede PDMR 11.441599 752 (of which 278 were sold and 474 retained) N/A Single Transaction
(Chief Quality & Regulatory Affairs Officer)
Elga Lohler PDMR 11.441599 4,247 (of which 1,690 were sold and 2,557 retained) N/A Single Transaction
(Chief HR Officer)
Vasant Padmanabhan PDMR 11.441599 3,436 (of which 1,276 were sold and 2,160 retained) N/A Single Transaction
(President Research & Development ENT)
Scott Schaffner PDMR 11.441599 2,496 (of which 927 were sold and 1,569 retained) N/A Single Transaction
(President Sports Medicine)
All figures in these columns are stated to 6 decimal places where applicable.
iii. PARTIAL VESTING OF 2023 DEFERRED BONUS SHARE AWARDS MADE UNDER THE
GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 9 March 2023 with
vesting in equal tranches on the first, second and third anniversary of grant.
A number of Shares were sold to cover taxation obligations arising on the
vesting of the awards. The number of Shares acquired includes the dividend
equivalent Shares which participants receive on vested Shares.
The following relates to individuals included in the below notification:
Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Partial vesting on 9 March 2025 of Deferred Bonus Share awards, granted on 9
March 2023 under the Smith & Nephew Global Share Plan 2020, and subsequent
sale of shares to cover tax liability
Date of Transaction 9 March 2025 (vesting) and 10 March 2025 (market sale)
Place of Transaction London Stock Exchange (XLON)
Name Price (£) Volume Aggregated information
(Position) Status
Helen Barraclough PDMR 11.441599 1,761 (of which 830 were sold and 931 retained) N/A Single Transaction
(Group General Counsel and Company Secretary)
Paul Connolly PDMR 11.441599 1,995 (of which 682 were sold and 1,313 retained) N/A Single Transaction
(President, Global Operations)
Phil Cowdy PDMR 11.441599 1,897 (of which 895 were sold and 1,002 retained) N/A Single Transaction
(Chief Corporate Development and Corporate Affairs Officer)
Craig Gaffin PDMR 11.441599 590 (of which 176 were sold and 414 retained) N/A Single Transaction
(President, Global Orthopaedics)
Mizanu Kebede PDMR 11.441599 2,040 (of which 755 were sold and 1,285 retained) N/A Single Transaction
(Chief Quality & Regulatory Affairs Officer)
Elga Lohler PDMR 11.441599 2,985 (of which 1,187 were sold and 1,798 retained) N/A Single Transaction
(Chief HR Officer)
Vasant Padmanabhan PDMR 11.441599 2,429 (of which 902 were sold and 1,527 retained) N/A Single Transaction
(President Research & Development ENT)
Alison Parkes PDMR 11.441599 1,055 (of which 476 were sold and 579 retained) N/A Single Transaction
(Chief Compliance Officer)
Scott Schaffner PDMR 11.441599 975 (of which 362 were sold and 613 retained) N/A Single Transaction
(President Sports Medicine)
All figures in these columns are stated to 6 decimal places where applicable.
iv. PARTIAL VESTING OF 2024 DEFERRED BONUS SHARE AWARDS MADE UNDER THE
GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 8 March 2024 with
vesting in equal tranches on the first, second and third anniversary of grant.
A number of Shares were sold to cover taxation obligations arising on the
vesting of the awards. The number of Shares acquired includes the dividend
equivalent Shares which participants receive on vested Shares.
The following relates to individuals included in the below notification:
Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Partial vesting on 8 March 2025 of Deferred Bonus Share awards, granted on 8
March 2024 under the Smith & Nephew Global Share Plan 2020, and subsequent
sale of shares to cover tax liability
Date of Transaction 8 March 2025 (vesting) and 10 March 2025 (market sale)
Place of Transaction London Stock Exchange (XLON)
Name Price (£) Volume Aggregated information
(Position) Status
Helen Barraclough PDMR 11.441599 3,208 (of which 1,513 were sold and 1,695 retained.) N/A Single Transaction
(Group General Counsel and Company Secretary)
Paul Connolly PDMR 11.441599 3,373 (of which 1,153 were sold and 2,220 retained.) N/A Single Transaction
(President, Global Operations)
Phil Cowdy PDMR 11.441599 3,456 (of which 1,630 were sold and 1,826 retained.) N/A Single Transaction
(Chief Corporate Development and Corporate Affairs Officer)
Craig Gaffin PDMR 11.441599 1,908 (of which 567 were sold and 1,341 retained.) N/A Single Transaction
(President, Global Orthopaedics)
Rohit Kashyap (President, Advanced Wound Management and Global Commercial PDMR 11.441599 3,778 (of which 1,125 were sold and 2,653 retained) N/A Single Transaction
Operations)
Mizanu Kebede PDMR 11.441599 3,880 (of which 1,434 were sold and 2,446 retained.) N/A Single Transaction
(Chief Quality & Regulatory Affairs Officer)
Elga Lohler PDMR 11.441599 4,839 (of which 1,927 were sold and 2,912 retained.) N/A Single Transaction
(Chief HR Officer)
Vasant Padmanabhan PDMR 11.441599 4,868 (of which 1,808 were sold and 3,060 retained.) N/A Single Transaction
(President Research & Development ENT)
Alison Parkes PDMR 11.441599 1,875 (of which 885 were sold and 990 retained.) N/A Single Transaction
(Chief Compliance Officer)
Scott Schaffner PDMR 11.441599 6,046 (of which 2,245 were sold and 3,801 retained.) N/A Single Transaction
(President Sports Medicine)
All figures in these columns are stated to 6 decimal places where applicable.
Philip Horner
Group Deputy Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477100
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFLFFEVFILLIERecent news on Smith & Nephew
See all newsREG - Smith & Nephew Plc - Director/PDMR Shareholding
AnnouncementREG - Smith & Nephew Plc - Total Voting Rights
AnnouncementREG - Smith & Nephew Plc - Result of AGM
AnnouncementREG - Smith & Nephew Plc - Smith+Nephew First Quarter 2025 Trading Update
AnnouncementREG - Smith & Nephew Plc - Holding(s) in Company
Announcement